The phone goes at eleven at night. There's a donor heart, and it's coming here. In a few hours that organ is going into a patient who is, right now, sitting on a ward waiting for you. In this episode Mike and Calum work through heart and lung transplantation from the listing call to the handover on the unit — the twelve hours in the middle. This is the theatre half; the postoperative ICU episode is separate. Please note: the drugs and doses discussed are Wythenshawe-specific local protocol, and are given as a worked example of how one centre does it. Take the principles, and check your own guidelines for the numbers. We start upstream of theatre — candidacy as a gift of life, why the patients being transplanted now are sicker and more borderline than a decade ago, and why compliance and mental health belong in that conversation. Then the middle-of-the-night listing assessment: what the reg is actually there to check, and what's already been done for you. Then into theatre. Preparation that has to happen before the patient arrives (products in the fridge, six units of red cells from the start, pacemaker to fixed mode, immunosuppression before they leave the ward). Induction drugs, including the vitamin K that stops the rebound phenomenon in a warfarinised LVAD explant. And a proper walk through the lines — why the femoral venous sheath is an escape route for a balloon pump wire, why the right-sided line is shorter to dodge the caval snare, and the Swan you must remember to withdraw before bicaval cannulation. For lungs we cover risk stratification up to "extreme high risk" — where you cannulate the groin before you induce, with a primed circuit and two consultants plus an ECMO consultant scrubbed — lung isolation, and the elegant argument for VA-ECMO over full bypass. Then the first implant: inflating to 15–20 cmH₂O, loosening the PA clamp, the three causes of hypotension at that moment, and the deliberately austere protective strategy for a new lung (FiO₂ 0.21, 3–4 mL/kg, under 20 cmH₂O) because hyperoxia drives primary graft dysfunction. Finally the sharp end: the written escalation ladder coming off bypass — milrinone, dopamine and noradrenaline, then sequential pacing, then the balloon pump, then nitric at 20 ppm, then conversion to VA-ECMO — and why you do not re-heparinise. Plus vasoplegia and its most dangerous trap: give methylene blue to a patient who is actually in a low cardiac output state and you have put a brick wall in front of the heart. We finish with the TOE numbers for the pulmonary vein and PA anastomoses, and an end-of-case checklist that includes putting the vascath in yourself. Chapters (00:00) Cold open — a donor heart is coming (01:00) Candidacy: who gets a transplant, and the MDT (03:20) The middle-of-the-night listing assessment (05:10) Preparation before the patient arrives (06:40) Induction drugs — and vitamin K for LVAD explants (08:20) Lines, and the traps that catch people out (11:00) The extreme high-risk lung induction (12:40) Lung isolation and positioning (13:40) Baseline TOE and metabolic management (14:40) Why transplants need so much insulin (15:40) Antifibrinolytics: tranexamic acid and aprotinin (16:30) Why VA-ECMO beats bypass for lungs (18:00) The first lung in: de-airing and protective ventilation (20:00) ECMO flow problems on the table (20:50) Coming off bypass: the escalation ladder (23:40) Vasoplegia — and the methylene blue brick wall (25:40) Low-volume blood products (26:40) TOE after implantation: the PV and PA numbers (28:00) End of case, vascaths and handover Key takeaways A transplant is a gift of life — candidacy is an MDT decision, not a 3am one Build your escape routes at the start: a femoral sheath that will take a balloon pump wire, a short right-sided line to clear the caval snare, and a Swan withdrawn before bicaval cannulation For the sickest lungs, cannulate the groin before you induce — with the room already full of the right people VA-ECMO beats bypass for lung transplant: less anticoagulation, less bleeding, and the heart keeps beating Protect the new lung — room air, 3–4 mL/kg, under 20 cmH₂O — because hyperoxia drives primary graft dysfunction Coming off, follow the ladder: inotropes → pacing → IABP → nitric → VA-ECMO, and don't re-heparinise Be certain it's vasoplegia before giving methylene blue; in a low output state it is a brick wall in front of the heart Put the vascath in yourself in theatre rather than leaving it to the unit References / further reading Velleca A et al. ISHLT Guidelines for the Care of Heart Transplant Recipients. J Heart Lung Transplant 2023 Leard LE et al. ISHLT consensus document for the selection of lung transplant candidates. J Heart Lung Transplant2021 Snell GI et al. ISHLT Working Group report on primary graft dysfunction: definition and grading. J Heart Lung Transplant 2017 Ius F et al. Lung transplantation on cardiopulmonary support: VA-ECMO versus cardiopulmonary bypass. J Thorac Cardiovasc Surg 2012 Diamond JM et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013 Levin RL et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg 2004 Boer C et al. EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. 2017 This podcast is for medical education for healthcare professionals. It is not clinical advice. All drugs and doses discussed reflect local Wythenshawe protocol at the time of recording — always follow your own centre's guidelines and current local policy.